Ignite Creation Date:
2024-05-06 @ 7:50 PM
Last Modification Date:
2024-10-26 @ 3:15 PM
Study NCT ID:
NCT06154408
Status:
COMPLETED
Last Update Posted:
2023-12-15
First Post:
2023-11-22
Brief Title:
Evaluating the Impact of Omega-3 Fatty Acid Supplementation Soloways on Lipid Profiles in Adults With PPARG Polymorphisms
Sponsor:
SLAB SOLOWAYS
Organization:
SLAB SOLOWAYS
Study Overview
Official Title:
Evaluating the Impact of Omega-3 Fatty Acid Supplementation Soloways on Lipid Profiles in Adults With PPARG Polymorphisms A Randomized Double-blind Placebo-controlled Trial
Status:
COMPLETED
Status Verified Date:
2023-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
SOLIPARG
Brief Summary:
In this study 102 patients will be evenly randomized into two groups one set to receive omega-3 fatty acids and the other a placebo The process will be blinded ensuring that neither the researchers nor the participants will know which group they are in Each participant will take two capsules daily for a duration of 90 days with the active group receiving capsules containing 1000 mg of fish oil each All participants will be instructed to maintain their usual diet lifestyle and medication regimen
At the beginning and end of the study various health assessments including lipid panels and C-reactive protein measurements will be conducted Additionally DNA samples will be collected for genotyping to identify patients with specific PPARG gene polymorphisms leading to the creation of four distinct subgroups those receiving omega-3 with and without polymorphisms and those receiving placebo with and without polymorphisms
At the beginning and end of the study various health assessments including lipid panels and C-reactive protein measurements will be conducted Additionally DNA samples will be collected for genotyping to identify patients with specific PPARG gene polymorphisms leading to the creation of four distinct subgroups those receiving omega-3 with and without polymorphisms and those receiving placebo with and without polymorphisms
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None